Anthem Blue Cross California Adakveo (crizanlizumab Form
This procedure is not covered
Overview
This document addresses the use of Adakveo (crizanlizumab). Crizanlizumab is a monoclonal antibody that binds to and inhibits P-selectin, an adhesion protein found on the surface platelets and endothelial cells. In those with sickle cell disease, P-selectin promotes blood vessels \
HCPCS
J0791
Injection, crizanlizumab-tmca, 5 mg (Adakveo) (Effective 7/1/2020)
ICD-10 Diagnosis
D57.00-D57.819
Sickle Cell Disease
Document History
Revised: 05/19/2023
Ask this policy anything